论文部分内容阅读
目的探讨β-连环蛋白(β-catenin)在乳腺癌中的不同表达定位与临床病理特征及预后的关系。方法采用免疫组化方法检测271例乳腺癌患者中β-catenin的表达,并分析其不同表达定位与临床病理特征及预后的关系。结果 271例乳腺癌中有196例β-catenin呈阳性表达,阳性表达率为72.3%,其中87例(44.4%)为胞浆表达,109例(55.6%)为胞膜表达。β-catenin表达定位与乳腺癌淋巴结转移及组织学分级呈正相关(P=0.002和P=0.014),而与年龄、绝经状态、肿瘤大小、肿瘤类型、临床分期无关(P>0.05)。Kaplan-Meier生存分析显示β-catenin胞浆表达的乳腺癌患者总生存期(OS)和无病生存期(DFS)明显短于其胞膜表达的患者,差异有统计学意义(P=0.015和P=0.023)。Cox比例风险回归分析显示β-catenin表达定位是影响乳腺癌患者预后的危险因素(P=0.025和P=0.014),但不是独立危险因素(P=0.546和P=0.919)。结论β-catenin在乳腺癌中的不同表达定位提示不同的预后价值,β-catenin在乳腺癌细胞浆中表达可作为肿瘤预后不良的一个参考指标。
Objective To investigate the relationship between the expression of β-catenin and clinicopathological features and prognosis in breast cancer. Methods The expression of β-catenin in 271 cases of breast cancer was detected by immunohistochemistry. The relationship between the expression of β-catenin and clinicopathological features and prognosis was analyzed. Results There were 196 cases of β-catenin in 271 cases of breast cancer, the positive expression rate was 72.3%. 87 cases (44.4%) were cytoplasm and 109 cases (55.6%) were membrane-expressed. The expression of β-catenin was positively correlated with lymph node metastasis and histological grade in breast cancer (P = 0.002 and P = 0.014), but not with age, menopause, tumor size, tumor type and clinical stage (P> 0.05). Kaplan-Meier survival analysis showed that the overall survival and the disease-free survival (DFS) of breast cancer patients with cytoplasmic expression of β-catenin were significantly shorter than those of their cytoplasm (P = 0.015 and P = 0.023). Cox proportional hazards regression analysis showed that β-catenin expression was a risk factor for prognosis in breast cancer patients (P = 0.025 and P = 0.014), but not an independent risk factor (P = 0.546 and P = 0.919). Conclusion The different expression and localization of β-catenin in breast cancer suggest different prognostic value. The expression of β-catenin in cytoplasm of breast cancer can be used as a reference index for poor prognosis.